Claude

People & Governance

Governance grade: C+ – Religare is in a genuine turnaround under new promoters (Burman family / Dabur), but the deep scars of the erstwhile promoter fraud, the contentious takeover battle, unresolved ESOP litigation, and a board still being constituted mean governance remains a work in progress rather than a solved problem.

The People Running This Company

The most important governance fact at Religare is that there is no single executive leader at the holding company level. The company operates as a Core Investment Company (CIC) with a CFO running the show on an interim basis while subsidiary heads run their respective businesses. The Burman family became promoters only in February 2025, and the board reconstitution with promoter nominees happened in July 2025. Three Burman family members – Anand Chand Burman, Mohit Burman, and Aditya Chand Burman – were proposed as additional directors in November 2025 (pending RBI approval). Jimeet Modi (Samco Group founder) was also inducted. Senior hires include Babu Rao (Group General Counsel, ex-Bajaj Finance) and Indranil Choudhury (Group CHRO, ex-UTI MF).

The leadership bench is thin but being actively built. The key risk is that there is no CEO or MD at the parent level, and critical subsidiary leadership hiring (NBFC, housing finance) is still ongoing.

What They Get Paid

Individual executive compensation for the current management team is not disclosed in the available data. The standalone entity (REL) is a holding company with only ~34 employees and has been loss-making for 4 of the last 5 years. Employee costs at the HoldCo have declined from 37.4 Cr in FY2024 to 26.1 Cr in FY2025, reflecting the exit of Rashmi Saluja and her associated costs.

Given the loss-making HoldCo, the absence of disclosed individual executive pay, and the ESOP overhang, compensation governance remains opaque. On the positive side, the Burman family members serve as non-executive directors and are not drawing known executive compensation from REL.

Are They Aligned?

Ownership and Control: The Burman family went from 0% promoter to 25.7% via a contested open offer at 235/share in Feb 2025, and has since increased to 26.3%. On full warrant conversion, promoter holding will reach ~29.75%. This is meaningful skin in the game – the family invested ~2,100 Cr in the open offer and committed 750 Cr more through preferential warrants.

Capital Infusion (Warrants): REL raised 1,500 Cr via preferential warrants at 235/share (Jul 2025). The Burman family committed 750 Cr (half), with Hindustan Times Media, Ashish Dhawan, and JM Financial providing the other half. As of Q3 FY26, only 410 Cr has been received (375 Cr upfront + 35 Cr conversion). Remaining conversion is due within 18 months. Deployment: 256 Cr infused into Care Health (rights issue), 25 Cr to broking, 20 Cr to housing, 75 Cr for REL debt repayment.

Insider Activity: No disclosed insider transactions in the structured data. The promoter holding has modestly increased from 25.7% to 26.3%, suggesting small open market purchases or creeping acquisition.

Related-Party Behavior: The most significant historical related-party issue was the Malvinder/Shivinder Singh era fraud – ~2,397 Cr siphoned from Religare Finvest through sham corporate loans. Charges were formally framed against the Singh brothers in Jan 2025 and trial is underway. All legacy loans have been written off. The LVB fixed deposit matter (750 Cr, fully provisioned) remains sub-judice in Delhi High Court.

Current related-party behavior under the Burmans appears reasonable: capital infusion is flowing to subsidiaries per the stated plan, and REL has been made debt-free. However, the Burman family also has stakes in Aviva Life Insurance and General Sompo Insurance, which could create potential conflicts with Care Health Insurance.

Demerger: In Feb 2026, the board approved demerging financial services (broking, NBFC, housing) into RFL, which will be separately listed by Q1 FY28 (15-18 months). Shareholders get 1 RFL share for every 1 REL share. This is a shareholder-friendly move to reduce holding company discount, but execution risk is real.

Board Quality

Strengths: Malla brings audit expertise and institutional memory as the longest-serving current director. Somani and Lamba were added post-takeover to strengthen independent oversight. New Group hires (General Counsel from Bajaj Finance, CHRO from UTI MF) improve professional bandwidth. Jimeet Modi (Samco founder) would add fintech and capital markets depth.

Weaknesses: No board member has deep health insurance domain expertise, which is critical since Care Health is the primary value driver. The board lacks a dedicated technology expert despite the digital transformation agenda. Multiple investors on earnings calls have requested Burman family participation in investor communication – their absence is notable and undermines trust-building. There is no CEO or MD at the holding company level.

Prior Governance Failures: InGovern flagged (Jul 2025) that Pratap Venugopal served simultaneously as REL's external legal counsel and Care Health's independent director – a conflict that was not transparently disclosed. The entire Saluja era (2018-2025) was marked by governance breakdowns: self-granted ESOPs, resistance to the Burman open offer on "fit and proper" grounds that SEBI rejected, insider trading allegations (SEBI show-cause notice), and ED investigations into conspiracy and cheating.

The Verdict

Strongest positives:

The Burman family (Dabur promoters, ~180 years of business heritage) have committed significant capital (~2,800 Cr total via open offer + warrants), made REL debt-free, cleaned up legacy fraud issues at RFL (RBI CAP removed Jul 2025, fraud tags lifted), and initiated a value-unlocking demerger. The return of regular earnings calls after a long gap signals improved transparency intent. Credit ratings across subsidiaries are being upgraded. The appointment of senior professionals (General Counsel, CHRO, Broking MD) from reputable institutions is encouraging.

Real concerns:

The company is being run by a CFO on an interim basis with no MD/CEO at the holding company. Individual executive compensation is not disclosed. The ESOP clawback from former chairperson Rashmi Saluja remains unresolved and sub-judice. Warrants are underwater (issue price 235 vs market ~226), creating conversion uncertainty for non-promoter investors. The Burman family's look-through holding in Care Health is only ~18-19%, below the 25% IRDAI threshold required for promoter status at the insurance subsidiary – this structural gap must be addressed. Investor calls show persistent demand for direct communication from the Burman family, which has not been met.

What would cause an upgrade:

Appointment of a credible CEO/MD at REL, successful completion of the demerger with RFL listing, ESOP clawback resolution, Burman family increasing economic stake past 30%, and direct promoter participation in investor communication.

What would cause a downgrade:

Non-promoter warrant holders choosing not to convert, regulatory complications delaying the demerger, new related-party concerns involving the Burman family's other insurance interests (Aviva, General Sompo), or failure to hire competent business leaders for the NBFC restart.